307 related articles for article (PubMed ID: 25342313)
1. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
3. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma.
Olszewski AJ; Winer ES; Castillo JJ
Leuk Res; 2014 Aug; 38(8):866-73. PubMed ID: 24837081
[TBL] [Abstract][Full Text] [Related]
4. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma.
Williams JN; Rai A; Lipscomb J; Koff JL; Nastoupil LJ; Flowers CR
Cancer; 2015 Jun; 121(11):1800-8. PubMed ID: 25675909
[TBL] [Abstract][Full Text] [Related]
5. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
6. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features of rituximab plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma].
Feng J; Wu J; Song Y; Su L; Zhang M; Li W; Hu Y; Zhang X; Gao Y; Niu Z; Feng R; Wang W; Peng J; Ouyang X; Li X; Wu C; Zhang W; Zeng Y; Xiao Z; Liang Y; Zhuang Y; Wang J; Sun Z; Bai H; Cui T
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):309-13. PubMed ID: 24759018
[TBL] [Abstract][Full Text] [Related]
8. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis.
Diem S; Ess S; Cerny T; Früh M; Hitz F
Eur J Intern Med; 2014 Jul; 25(6):577-82. PubMed ID: 24881010
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
10. Patterns of failure in advanced stage diffuse large B-cell lymphoma patients after complete response to R-CHOP immunochemotherapy and the emerging role of consolidative radiation therapy.
Shi Z; Das S; Okwan-Duodu D; Esiashvili N; Flowers C; Chen Z; Wang X; Jiang K; Nastoupil LJ; Khan MK
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):569-77. PubMed ID: 23540349
[TBL] [Abstract][Full Text] [Related]
11. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
12. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
14. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.
Delarue R; Tilly H; Mounier N; Petrella T; Salles G; Thieblemont C; Bologna S; Ghesquières H; Hacini M; Fruchart C; Ysebaert L; Fermé C; Casasnovas O; Van Hoof A; Thyss A; Delmer A; Fitoussi O; Molina TJ; Haioun C; Bosly A
Lancet Oncol; 2013 May; 14(6):525-33. PubMed ID: 23578722
[TBL] [Abstract][Full Text] [Related]
15. Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Flinn IW; Spigel DR; Clark BL; Griner PL; Vazquez ER; Doss HH; Shipley D; Franco LA; Burris HA; Greco FA;
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):44-50. PubMed ID: 20223728
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma.
Hershman DL; McBride RB; Eisenberger A; Tsai WY; Grann VR; Jacobson JS
J Clin Oncol; 2008 Jul; 26(19):3159-65. PubMed ID: 18591554
[TBL] [Abstract][Full Text] [Related]
17. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma.
Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS
Ann Hematol; 2012 Sep; 91(9):1383-91. PubMed ID: 22526364
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
[TBL] [Abstract][Full Text] [Related]
19. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
Pfreundschuh M; Poeschel V; Zeynalova S; Hänel M; Held G; Schmitz N; Viardot A; Dreyling MH; Hallek M; Mueller C; Wiesen MH; Witzens-Harig M; Truemper L; Keller U; Rixecker T; Zwick C; Murawski N
J Clin Oncol; 2014 Dec; 32(36):4127-33. PubMed ID: 25403207
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with transformed lymphoma in the rituximab era.
Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]